8-K: NeOnc Technologies Phase 2a Trial Shows Promising Survival Data

NeOnc Technologies announced positive top-line results from the Phase 2a portion of its NEO100-01 clinical trial for recurrent IDH1 mutant high-grade glioma, demonstrating a significant improvement in overall survival.

Summary

• NeOnc Technologies' Phase 2a trial for NEO100-01 in recurrent IDH1 mutant high-grade glioma met its primary endpoint.
• The trial showed a median overall survival of 26.1 months, a substantial increase compared to the 6-9 months typically seen with current salvage therapies.
• Progression-free survival at six months (PFS6) was 48.9%, significantly outperforming the 20% benchmark.
• The company plans to present these results to the FDA and pursue a Phase 3 accelerated approval pathway.
• NEO100 is delivered intranasally, bypassing the blood-brain barrier via cranial nerves.
• The drug works through multiple mechanisms, including inducing ER stress, inhibiting the sodium-potassium ATPase pump, and inhibiting RAS signaling.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development, with strong clinical trial results significantly exceeding benchmarks and offering substantial hope for patients with a critical unmet need.

Positives

• Median overall survival of 26.1 months, a 4x to 5x improvement over the 6-9 month benchmark for recurrent IDH1 mutant high-grade glioma.
• Progression-free survival at six months (PFS6) of 48.9%, significantly exceeding the 20% benchmark with a p-value of 0.0047.
• 86.7% survival at six months and 60.9% at 12 months post-recurrence.
• Disease control rate of 66.7% (including partial response and stable disease).
• Favorable tolerability profile observed.
• The intranasal delivery method is novel and non-invasive.
• Positive results from cumulative Phase 1 and Phase 2 data show 55% long-term survivors (>1 year post-recurrence) with a median OS of 2.2 years.
• The company has IND approval for all four drugs and is seeking approval in Israel.

Negatives

• The trial was a single-arm design, and future confirmatory results will require a randomized controlled trial.
• While PFS6 was met, the company acknowledges that overall survival is the key metric for pivotal trials.
• Some patients may not show immediate radiographic response but still experience extended survival due to the drug's cytostatic nature.

Risks

• Results of preclinical studies and early clinical trials may not be predictive of results in future clinical trials.
• Announced or published data may change as more patient data becomes available and are subject to audits and verification procedures.
• Product candidates are in clinical stages of development and are not approved for commercial sale and might never receive regulatory approval or become commercially viable.
• The company encourages review of the Risk Factors section of its SEC filings for a comprehensive understanding of risks.

Future Outlook

The company is preparing to meet with the FDA to discuss a proposed Phase 3 accelerated approval design, which will be a randomized trial against lomustine, with median overall survival as the primary endpoint and a pre-specified interim analysis to support accelerated approval.

Management Comments

• NEO100-01, Phase 2 met its primary endpoint. Survival is the standout result. Median overall survival was 26.1 months, measured from the start of NEO100 at recurrence, a setting which current salvage therapy delivers roughly only six to nine months.
• We are the only company that is doing intranasal delivery for brain cancer at this time.
• We have met all of our primary endpoints, as you heard. Life expectancy was increased by 4x to 5x, as you heard.
• This is one of the most exciting things we've seen come along in the last decade.
• If the results carry through as we expect they will on the next study, you've got a paradigm shift in the treatment of this disease. It's that simple.
• We have been very active with our compassionate use applications. We have used it in various patients that do not qualify for the trial.
• Especially for the pediatric population. We have used the largest amount of compassionate uses in the pediatric platform. And if you go on our website, you can see some of the progress these kids are making and the drug is doing Gods work.

Industry Context

StockSavvy.ai notes that the results for NEO100-01 address a significant unmet need in recurrent high-grade gliomas, particularly IDH1 mutant types, where current treatment options are limited and survival rates are poor. The intranasal delivery platform represents a novel approach in brain cancer therapy.

Comparison to Industry Standards

• Compared to historical salvage therapy for recurrent IDH1 mutant high-grade glioma, which yields a median overall survival of 6-9 months, NEO100-01 achieved 26.1 months.
• The progression-free survival at six months (PFS6) of 48.9% significantly surpasses the 20% benchmark used for signal-seeking trials.
• Cross-trial comparisons suggest that while other trials like INDIGO focused on Grade II tumors and STELLAR did not show benefit in Grade IV recurrent patients, NEO100-01 demonstrated efficacy in the challenging recurrent Grade III and IV IDH1 mutant population.
• The observed survival tail post-20 months and 60.9% 12-month survival rate are notably higher than typical outcomes for this patient group.

Stakeholder Impact

• Shareholders: Potential for significant positive impact on stock valuation due to promising clinical trial results and a clear path towards potential regulatory approval.
• Patients: Offers a new, potentially life-extending treatment option for a patient population with a critical unmet need in recurrent high-grade glioma.
• Healthcare Providers: Provides a novel therapeutic approach and delivery method for treating a difficult-to-treat cancer.
• Regulators (FDA): Will review the data to determine eligibility for accelerated approval and future confirmatory trials.

Next Steps

• Present results to the FDA.
• Discuss a proposed Phase 3 accelerated approval design with the FDA.
• Seek FDA guidance for an accelerated approval design with an interim analysis.
• Initiate clinical trials in Abu Dhabi.
• Obtain approval in Israel.

Key Dates

Recommendation

The Phase 2a results for NEO100-01 are exceptionally strong, significantly exceeding benchmarks for overall survival and progression-free survival in a critical unmet need population. The intranasal delivery is innovative, and the company has a clear regulatory path forward with the FDA. The data suggests a potential paradigm shift in treating recurrent IDH1 mutant high-grade gliomas, warranting a strong buy recommendation.

Keywords

NEO100-01, high-grade glioma, IDH1 mutant, recurrent brain cancer, intranasal delivery, overall survival, progression-free survival, clinical trial